Arévalo MFG, Badia FJJ, Arciniega AA

Idioma: Español
Referencias bibliográficas: 26
Paginas: 109-110
Archivo PDF: 84.38 Kb.

FRAGMENTO

Introducción
Las miopatías inflamatorias (MI) son un grupo heterogéneo de enfermedades caracterizadas por debilidad muscular proximal e inflamación del musculoesquelético. Las MI han sido clasificadas en cinco grupos: polimiositis idiopática primaria, dermatomiositis idiopática primaria asociada a malignidad, juvenil asociada a vasculitis y asociada a enfermedad vascular colágena.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis. New Engl J Med. 1975; 292: 344.

2. Selva O’Callaghan A, Trallero AE. Inflammatory Myopathies. Dermatomyositis, polymyositis and inclusion body myositis. Reumatol Clin. 2008; 4 (5): 197-206.

3. Leon G, Blancas F. Dermatomiositis. PAC Dermatología, Intersistemas, 2010, pp. 21-24.

4. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985; 12 (6): 1140.

5. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008; 10: 333-340.

6. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol. 2007; 19: 523-529.

7. Smith ES, Hallman JR, De Luca AM et al. Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009; 31: 61-67.

8. Stringer E, Ota S, Bohnsack J et al. Diversity of treatment approach juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatments tudy. Arthritis Rheum. 2008; 58: S255.

9. Rouster-Stevens KA, Gursahaney A, Ngai KL et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008; 59: 222-226.

10. Seshadri R, Feldman BM, Ilowite N et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008; 59: 989-995.

11. Riley P, Maillard SM, Wedderburn LR et al. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004; 43: 491-496.

12. Cooper MA, Willingham DL, Brown DE et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007; 56: 3107-3111.

13. Bader-Meunier B, Decaluwe H, Barnerias C et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French autoimmunity and rituximab registry. J Rheumatol. 2011; 38: 1436-1440.

14. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004; 15: 35-39.

15. García-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology. 2004; 209: 247-248.

16. Manlhiot C, Tyrrell PN, Liang L et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008; 121: e626-e630.

17. Ruperto N, Pistorio A, Oliveira S et al. A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate. ACR Meeting (2012). Arthritis Rheum. 2012; 64: S1042.

18. McNeil MM, Brown JM, Hutwagner LC, Schiff TA. Evaluation of therapy for Nocardia asteroides complex infections. Infect Dis Clin Prac. 1995; 4: 287.

19. Uhde KB, Pathak S, McCullum I Jr et al. Antimicrobial-resistant Nocardia isolates, United States, 1995-2004. Clin Infect Dis. 2010; 51: 1445-1448.

20. Brown-Elliott BA, Biehle J, Conville PS et al. Sulfonamide resistance in isolates of Nocardia spp. from a US multicenter survey. J Clin Microbiol. 2012; 50: 670-672.

21. Ambrosioni J, Lew D, Garbino J. Nocardiosis: updated clinical review and experience at a tertiary center. Infection. 2010; 38: 89-97.

22. Yshibashi Y, Watanabe R, Hommura S, Koyama A, Ishikawa T, Mikami Y. Endogenous Nocardia asteroides endophthalmitis in a patient with systemic lupus erythematosus. Br Ophthalmol. 1990; 74: 433-436.

23. La Civita L, Battiloro R, Celano M. Nocardia pleural empiema complicating anti-Jo1 positive polymyositis during immunoglobulin and steroid therapy. J Rheumatol. 2001; 28: 215-217.

24. Auzary C, Mouthon L, Soilleux M, Cohen P, Boiron P, Guillevin L. Localized subcutaneous Nocardia farcinica abscess in a woman with overlap syndrome between systemic scleroderma and polymyositis. Ann Med Interne. 1999; 150: 582-584.

25. Yap EY, Fam HB, Leong KP, Buettner H. Nocardia chroidal abscess in a patient with systemic lupus erythematosus. Aust N Z J Ophthalmic. 1998; 26: 337-338.

26. Korkmaz C, Aydini A, Erol N et al. Widespred nocardiosis in two patients with Behcet disease. Clin Exp Rheumatol. 2001; 19: 459-462.